1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Tackling Parkinson's: Pharma Two B tests FDC in Phase IIb

 
• By Donna Young

As the world gets ready to mark Parkinson's Disease Awareness Month in April, the harsh reality for patients is the fact there remains no cure and few effective treatments for the chronic, progressive neurological condition, which affects up to one in every 100 people over 60 years.

As the world gets ready to mark Parkinson's Disease Awareness Month in April, the harsh reality for patients is the fact there remains no cure and few effective treatments for the chronic, progressive neurological condition, which affects up to one in every 100 people over 60 years.

The symptoms of Parkinson's, a motor system disorder, which results from the loss of dopamine-producing brain cells, usually consist of trembling in the hands, arms, legs, jaw and face; stiffness...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

More from Therapy Areas

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.